ÀǾàǰ ¢Æ China¡¯s Guidebook for Pharmaceutical Patent Protection China is expected to become the fifth largest pharmaceuticals market in the world by 2010, with a growth rate of 20-25% per annum over the next three years. As China joins the World Trade Organization (WTO) and becomes more integrated into the global economy, increasing numbers of pharmaceutical companies and manufacturers are looking to access the lucrative Chinese market. (Informa Healthcare Ltd ¹ßÇà, 2007³â 3¿ù ¹ßÇà, °¡°Ý: US$2,900 (PDF)).
³óÈÇÐ ¢Æ Adjuvants & Additives This new report from Agrow is a full update of the 2003 report. This report is a comprehensive analysis of the world market for agrochemical adjuvants and will inform you about: The regulatory environment for registering and commercialising adjuvants around the world, allowing you to target the most accessible markets and prepare for those that are more challenging. (Informa Healthcare Ltd ¹ßÇà, 2006³â 11¿ù ¹ßÇà, °¡°Ý: US$1,250).
µ¿¹°¾àǰ ¢Æ European Animal Health Markets & Opportunities 'Worth in excess of ¢æ4 billion, sales of animal health products in the European Union¡¯s 27 member countries are responsible for well over a quarter of global market sales.' This report examines the size, structure and development of the EU market, and profiles the European operations of leading animal health product manufacturers. (Informa Healthcare Ltd ¹ßÇà, 2007³â 5¿ù ¹ßÇà, °¡°Ý: US$1,560).
ÀǾàǰ ¢Æ Scrip Yearbook 2007 Scrip¡¯s annual review of the year, Scrip Yearbook 2007 is your guide to all the key facts, events and issues of the last 12 months from across the pharmaceutical and biotechnology industries. Collected and organised from coverage in Scrip World Pharmaceutical News, the respected source of biopharmaceutical industry news, this new updated report provides a complete and concise tool, covering all levels of the industry and recent developments. (Informa Healthcare Ltd ¹ßÇà, 2007³â 1¿ù ¹ßÇà, °¡°Ý: US$1,670).
µ¿¹°¾àǰ ¢Æ Livestock Performance Products and Markets Following the EU ban of performance enhancers that are of high risk to humans, interest in safe and effective performance enhancing products is on the increase. As a result there are new opportunities emerging to sell these products into other markets or to develop new products that can act as safe alternatives. (Informa Healthcare Ltd ¹ßÇà, 2007³â 4¿ù ¹ßÇà, °¡°Ý: US$1,560).